👉 Choose Owkin if you need…
- People who spend real hours each week on ai healthcare, wellness & medical
- Anyone testing the space without an upfront budget
- Buyers who want a highly rated, well-established option
Owkin is built for ai healthcare, wellness & medical users on a free tier plan, while Recursion targets ai healthcare, wellness & medical workflows on a free tier model — here's how they stack up feature by feature.
| Comparison | Owkin | Recursion |
|---|---|---|
| Pricing & free tier | Freemium | Freemium |
| Starting price | Free, paid plans available | Free, paid plans available |
| Free trial / credits | Exact allowance not recorded | Exact allowance not recorded |
| Credit card required | No credit card required | No credit card required |
| Foundation model | Multi-model | Fine-tuned |
| BYOK / platform control | BYOK supported | Locked |
| Category & tags | AI Healthcare, Wellness & Medical | AI Healthcare, Wellness & Medical |
| Core features & strengths |
|
|
| Community rating | 4.5(0) | 4.5(0) |
| Get started | Visit Owkin | Visit Recursion |
Owkin is an AI biotechnology company focused on accelerating drug discovery and research in medicine. It combines a large network of patient data, an autonomous AI scientist called K Pro, and wet lab validation to help generate and test biological hypotheses. Owkin works with biopharma companies on questions across oncology, neuroscience, cardiology, stroke, pulmonary disease, obesity, and ageing research. The tool is aimed at pharmaceutical companies, research institutions, and biomedical scientists looking to speed up drug R&D using AI combined with real patient data and lab validation, rather than individual consumers or general businesses.
Recursion is a biotechnology company that uses an AI-driven platform to discover and develop new medicines. It combines automated wet-lab experiments with machine learning models in what it calls a "lab-in-the-loop" system, mapping disease biology, designing drug candidates, and advancing them toward clinical trials. The company maintains its own pipeline of investigational drugs in areas like oncology and rare disease, and also partners with pharmaceutical companies to apply its technology to specific drug discovery challenges. This is not a consumer software product but a platform and company aimed at pharmaceutical partners, investors, and researchers interested in AI-driven biology and drug development, rather than individual end users seeking a subscription tool.
Give both tools the same brief and source material. Judge the final deliverable after corrections: factual accuracy, editable output, and how much work remains before you can use it.
Count retries, exports, premium models and any separate hosting or API charges. A free allowance is useful for evaluation, but it does not establish the cost of a recurring production workload.
Confirm which files, project data and settings you can export. Bringing your own API key is different from owning the application code or being able to run the product independently.
Check the terms for the exact plan and feature you intend to use. Commercial permission, private projects and protection against intellectual property claims are different commitments.